出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2016/11/29 19:56:10」(JST)
Clinical data | |
---|---|
Trade names | Myocrisin |
AHFS/Drugs.com | Multum Consumer Information |
License data |
|
Pregnancy category |
|
Routes of administration |
Intramuscular |
ATC code | M01CB01 (WHO) |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | High[1] |
Biological half-life | 6-25 days[1] |
Excretion | Urine (60-90%), faeces (10-40%)[1] |
Identifiers | |
Systematic (IUPAC) name: Sodium 2-(auriosulfanyl)-3-carboxypropanoate
|
|
CAS Number | 12244-57-4 |
PubChem (CID) | 16760302 |
ChemSpider | 7827788 Y |
UNII | E4768ZY6GM N |
ChEBI | CHEBI:35863 Y |
Chemical and physical data | |
Formula | C4H4AuNaO4S |
Molar mass | 367.939350590 |
3D model (Jmol) | Interactive image |
SMILES
|
|
InChI
|
|
(verify) |
Sodium aurothiomalate (INN, known in the United States as gold sodium thiomalate) is a gold compound that is used for its immunosuppressive anti-rheumatic effects.[2][3] Along with an orally-administered gold salt, auranofin, it is one of only two gold compounds currently employed in modern medicine.[4]
It is primarily given as a once or twice weekly by intramuscular injection for moderate-severe rheumatoid arthritis although it has also proven itself effective in treating tuberculosis.[5]
Its most common side effects are digestive (mostly dyspepsia, mouth swelling, nausea, vomiting and taste disturbance), vasomotor (mostly flushing, fainting, dizziness, sweating, weakness, palpitations, shortness of breath and blurred vision) or dermatologic (usually itchiness, rash, local irritation near to the injection site and hair loss) in nature, although conjunctivitis, blood dyscrasias, kidney damage, joint pain, muscle aches/pains and liver dysfunction are also common.[6] Less commonly, it can cause GI bleeds, dry mucous membranes and gingivitis.[6] Rarely it can cause: aplastic anaemia, ulcerative enterocolitis, difficulty swallowing, angiooedema, pneumonitis, pulmonary fibrosis, hepatotoxicity, cholestatic jaundice, peripheral neuropathy, Guillain–Barré syndrome, encephalopathy, encephalitis and photosensitivity.[6]
Its precise mechanism of action is unknown but is known that it inhibits the synthesis of prostaglandins.[4] It also modulates phagocytic cells and inhibits class II major histocompatibility complex-peptide interactions.[4] It is also known that it inhibits the following enzymes:[4][7]
Reports of favorable use of the compound were published in France in 1929 by Jacques Forestier. [8] The use of gold salts was then a controversial treatment and was not immediately accepted by the international community. Success was found in the treatment of Raoul Dufy's joint pain by the use of gold salts in 1940; "(The treatment) brought in a few weeks such a spectacular sense of healing, that Dufy ... boasted of again having the ability to catch a tram on the move." [9]
|title=
at position 60 (help)
Specific antirheumatic products / DMARDs (M01C)
|
|
---|---|
Quinolines |
|
Gold preparations |
|
Other |
|
|
Gold compounds
|
|||
---|---|---|---|
Gold(-I) |
|
||
Gold(I) |
|
||
Gold(II) |
|
||
Gold(I,III) |
|
||
Gold(III) |
|
||
Gold(V) |
|
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
リンク元 | 「金チオリンゴ酸」 |
関連記事 | 「aurothiomalate」 |
.